Anticancerimmunotherapyhasundergonealongevolvingjourneyfordecades,andhasbeendramaticallyappliedtomainstreamtreatmentsinoncologyinrecent5years.Thisprogressrepresentsanadvancedmilestonefollowingcytotoxicmedicineandtargetedtherapy.Cellularimmunityplaysapivotalroleintheimmuneresponsesofhoststotumorantigens.Suchimmunityisnotablysuppressedduringneoplasticprogressionduetoimmuno-editingprocesses.Cellularimmunitycanalsobeselectivelyreactivatedtocombatmalignancieswhileexploitingtheadvantagesofcontemporaryscientificbreakthroughsinmolecularimmunologyandgeneticengineering.Therapidadvancementofcellularimmunity-basedtherapeuticapproacheshasachievedhighefficacyincertaincancerpatients.Consequently,thelandscapeofoncologicmedicineandpharmaceuticalinnovationhastransformedrecently.Inthisregard,wepresentacomprehensiveupdateonclinicallyestablishedanti-cancertreatmentswithcellimmunityaugmentationasthemajormechanismofaction.
